TOThomas Oates

Thomas Oates

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Oates has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • “Epigenome-wide methylation profile of chronic kidney disease-derived arterial DNA uncovers novel pathways in disease-associated cardiovascular pathology.”

    by Athina Dritsoula, Maria Kislikova, Amin Oomatia, Amy P. Webster, Stephan Beck, Markella Ponticos, Ben Lindsey, Jill Norman, David C. Wheeler, Thomas Oates, et al.

    Chronic kidney disease (CKD) related cardiovascular disease (CVD) is characterized by vascular remodelling with well-established structural and functional changes in the vascular wall such as arterial stiffness, matrix deposition, and calcification. These phenotypic changes resemble pathology seen in ageing, and are likely to be mediated by sustained alterations in gene expression, which may be caused by epigenetic changes such as tissue-specific DNA methylation. We aimed to investigate tissue specific changes in DNA methylation that occur in CKD-related CVD. Genome-wide DNA methylation changes were examined in bisulphite converted genomic DNA isolated from the vascular media of CKD and healthy arteries. Methylation-specific PCR was used to validate the array data, and the association between DNA methylation and gene and protein expression was examined. The DNA methylation age was compared to the chronological age in both cases and controls. Three hundred and nineteen differentially methylated regions (DMR) were identified spread across the genome. Pathway analysis revealed that DMRs associated with genes were involved in embryonic and vascular development, and signalling pathways such as TGFβ and FGF. Expression of top differentially methylated gene HOXA5 showed a significant negative correlation with DNA methylation. Interestingly, DNA methylation age and chronological age were highly correlated, but there was no evidence of accelerated age-related DNA methylation in the arteries of CKD patients. In conclusion, we demonstrated that differential DNA methylation in the arterial tissue of CKD patients represents a potential mediator of arterial pathology and may be used to uncover novel pathways in the genesis of CKD-associated complications.


  • The Evolution of the Journal Club: From Osler to Twitter

    by Joel M. Topf, Matthew A. Sparks, Paul J. Phelan, Nikhil Shah, Edgar V. Lerma, Matthew P.M. Graham-Brown, Hector Madariaga, Francesco Iannuzzella, Michelle N. Rheault, Thomas Oates, et al.


  • Open Access

    Twitter-Based Journal Clubs: Additional Facts and Clarifications

    by Joel M Topf, Matthew A Sparks, Francesco Iannuzzella, Edgar Lerma, Thomas Oates, Paul J Phelan, Swapnil Hiremath

    We read the recently published paper on globalization of continuing professional development by Roberts et al with great interest. The authors should be congratulated on their idea as well as their execution of this novel way of evaluating and describing Twitter-based journal clubs. We would like to add to their article by providing some additional advantages and features of a Twitter-based online journal club to provide the reader with a more complete appreciation of their educational potential.


  • Cost comparison of online haemodiafiltration with high-flux haemodialysis

    by Thomas Oates, Jennifer Cross, Andrew Davenport

    Haemodiafiltration increases convective clearances, and online haemodiafiltration (OL-HDF) was introduced to reduce costs of producing large volumes of ultrapure water. Previous reports have suggested that OL-HDF may be a cost-saving therapy by reducing recombinant human erythropoietin requirements and those for other medications. We therefore costed OL-HDF with high-flux haemodialysis. Thirty-four patients dialysing (Tue/Thu/Sat) switched to OL-HDF, and 44 dialysing (Mon/Wed/Fri) remained on high-flux haemodialysis (HD) in a satellite dialysis centre. They were then prospectively followed for 12 months. Depending upon whether blood lines with a cuvette for measuring relative blood volume were used, OL-HDF was either slightly more expensive per session, by £1.16, as the cost of the reinfusion line outweighed any potential savings in 0.9% saline usage, or cheaper by £0.78 if standard blood lines were used. Although there were initial increased costs for more frequent testing of dialysis machine water quality. It could be argued that similar water quality is required for high-flux haemodialysis using dialysers with increased internal filtration. There was no cost saving in terms of recombinant human erythropoietin prescription, but whereas weekly phosphate binder costs increased in the high-flux haemodialysis cohort from £3.8 (range 1.9-14.8) to £5.0 (range 1.9-21.3; p=0.01), costs did not change with OL-HDF (£3.8, range 1.9-11.9). Depending upon the choice of blood lines, OL-HDF was either a slightly more expensive or a cheaper treatment per session compared with high-flux haemodialysis in our centre. Treatment with OL-HDF also led to modest cost savings on phosphate binders.


  • Haemodiafiltration Does Not Reduce the Frequency of Intradialytic Hypotensive Episodes when Compared to Cooled High-Flux Haemodialysis

    by Jennifer H. Pinney, Thomas Oates, Andrew Davenport

    Introduction: Intradialytic hypotension remains the commonest complication of outpatient haemodialysis (HD) treatments. On-line haemodiafiltration (HDF) has been reported to reduce the frequency of intradialytic hypotension. We introduced on-line HDF into our satellite dialysis program, and prospectively audited the effect of HDF on cardiovascular stability. Methods: 34 patients’ dialysis schedules (Tuesday/Thursday/Saturday) were converted to online post-dilutional HDF, and 44 patients’ dialysis schedules (Monday/Wednesday/Friday) remained on high-flux HD. Blood pressure and intra-treatment complications were monitored prospectively for 12 months. Results: There was no significant change in pre-treatment mean arterial blood pressure in the HDF group during the 12 months of the study (pre-treatment 113.7 ± 0.7 mm Hg vs. 109.3 ± 2.8 after 12 months), or for the HD cohort (113.9 ± 2.7 vs. 117.9 ± 2.6). However, the frequency of intradialytic hypotensive episodes was greater for the HDF cohort: 25.9 versus 16.5% in the HD cohort, p = 0.0116. During HDF, on average >16 litres of substitution fluid was used and the median temperature was 36°C (35°C–36°C), higher than the dialysate in the HD cohort which was 35°C (35°C–36°C), p < 0.05. Conclusion: In this study, HDF did not improve blood pressure control or reduce the frequency of intradialytic hypotensive episodes compared to high-flux HD using cooled dialysate.


  • Haemodiafiltration versus High-Flux Haemodialysis: Effects on Phosphate Control and Erythropoietin Response

    by Thomas Oates, Jennifer H. Pinney, Andrew Davenport

    Introduction: Haemodiafiltration (HDF) has been reported to improve erythropoietin (EPO) responsiveness and phosphate clearance. We prospectively audited the effect of HDF on EPO dosages, weight and serum phosphate. Methods: 34 patients dialyzing on Tu/Th/Sa switched to HDF, and 44 dialyzing on M/W/F remained on high-flux haemodialysis (HD) and were followed for 12 months. Results: Dialysis adequacy (Kt/V start HDF 1.56 ± 0.03 vs. HD 1.58 ± 0.04 and 12 months 1.55 ± 0.03 vs. 1.59 ± 0.03), haemoglobin (start 11.7 ± 0.3 vs. 11,8 ± 0.2 g/dl and end 11.5 ± 0.1 vs. 11.3 ± 0.3 g/dl), weight (start 69.8 ± 2.4 vs. 67.8 ± 2.5 kg and end 67.4 ± 2.5 vs. 66.1 ± 2.3 kg), or EPO prescription (start 83 (61–186) vs. 123 (71–225) IU/kg/weeks and 12 months 142 (48–188) vs. 124 (59–223) IU/kg/weeks) did not differ. There were no differences in serum albumin, CRP, calcium and parathyroid hormone. Serum beta-2-microglobulin (B2M) decreased with HDF (32.7 ± 1.9 vs. 28.1 ± 1.1 mg/l, p < 0.01), but not with HD (31.6 ± 1.4 vs. 31.5 ± 1.1 mg/l). Serum phosphate fell with HDF (start 1.48 ± 0.08 vs. 1.57 ± 0.07 mmol/l (p = NS); 3 months 1.35 ± 0.07 vs. 1.61 ± 0.08; 6 months 1.34 ± 0.06 vs. 1.57 ± 0.06, and 12 months 1.36 ± 0.07 vs. 1.67 ± 0.07, all p < 0.05). Conclusion: HDF did not lead to weight gain or improved EPO responsiveness in this prospective observational study. However, predialysis serum phosphate and B2M fell with HDF.


  • More on pneumonia: “Surviving Sepsis” campaign may contradict CURB score

    by Thomas M Oates

    Footnotes Competing interests None declared.